tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Kyverna Therapeutics initiated with an Outperform at William Blair

William Blair analyst Sami Corwin initiated coverage of Kyverna Therapeutics (KYTX) with an Outperform rating and $27 fair value estimate. Kyverna is a clinical-stage biotechnology company developing immune cell therapies that can induce long-term remissions for patients with severe autoimmune diseases without the need for chronic immunosuppression, the analyst tells investors in a research note. The firm believes the company is on track have the first FDA approved CAR-T for the treatment of an autoimmune disease.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1